«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 19

Page:

3644-3648

Research Field:

Publishing date:

Info

Title:

Efficacy and safety analysis of total oral medication IBiRd regimen in the treatment of patients with relapsed/refractory multiple myeloma

Author(s):

WANG Xiufeng¹; LI Ting²; ZI Youmei¹; LIU Xiankai¹; YANG Man¹; LYU Guoqing¹; WU Sun¹; HUANG Yan¹

1.Department of Hematology,the First Affiliated Hospital of Xinxiang Medical University,Xinxiang Key Laboratory for Molecular Diagnosis and Therapy of Lymphoma;2.Department of Blood Purification,Henan Weihui 453100,China.

Keywords:

IRD; Clarithromycin/Biaxin; relapsed/refractory multiple myeloma

PACS:

R733.3

DOI:

10.3969/j.issn.1672-4992.2023.19.021

Abstract:

Objective:To evaluate the efficacy and safety of total oral medication IBiRd regimen(Ixazomib + clarithromycin + lenalidomide + dexamethasone) on relapsed/refractory multiple myeloma.Methods:Retrospectively analyze 28 cases of relapsed/refractory multiple myeloma in our hospital from January 1,2020 to December 31,2021.The efficacy and adverse reactions after 2 cycles of treatment were summarized and analyzed.Results:28 patients were evaluated after 2 cycles of treatment.The clinical benefit rate was 78.6%.The objective response rate was 50%,among which very good partial response rate was 14.3%,partial response rate was 35.7%,minimal response rate was 28.6%,and adverse reactions were mild,mainly including fatigue,appetite loss,diarrhea and hematologic toxicity.Conclusion:The all-oral IBiRD regimen is an effective all-oral regimen for the treatment of relapsed and refractory myeloma with mild adverse effects.

References:

£Û1£ÝCOWAN AJ,GREEN DJ,KWOK M,et al.Diagnosis and management of multiple myeloma:a review£ÛJ£Ý.JAMA,2022,327(5):464-477.
£Û2£ÝÖйúҽʦЭ»áѪҺ¿Æҽʦ·Ö»á,ÖлªÒ½Ñ§»áѪҺѧ·Ö»á.Öйú¶à·¢ÐÔ¹ÇËèÁöÕïÖÎÖ¸ÄÏ£¨2022ÄêÐÞ¶©£©£ÛJ£Ý.ÖлªÄÚ¿ÆÔÓÖ¾,2022,61(5):480-487. Hematologist Branch of Chinese Medical Doctor Association,Hematology Branch of Chinese Medical Association.Guidelines for the diagnosis and treatment of multiple myeloma in China(revised in 2022)£ÛJ£Ý.Chinese Journal of Internal Medicine,2022,61(5):480-487.
£Û3£ÝMONTEITH BE,SANDHU I,LEE AS.Management of multiple myeloma:a review for general practitioners in oncology£ÛJ£Ý.Curr Oncol,2023,30(5):4382-4401.
£Û4£ÝMAOUCHE N,KISHORE B,JENNER MW,et al.Ixazomib,lenalidomide,and dexamethasone is effective and well tolerated in multiply relapsed(¡Ý2nd relapse) refractory myeloma:a multicenter real world UK experience£ÛJ£Ý.Leuk Lymphoma,2021,62(6):1396-1404.
£Û5£ÝTERPOS E,RAMASAMY K,MAOUCHE N,et al.Real-world effectiveness and safety of Ixazomib-lenalidomide-dexamethasone in relapsed/refractory multiple myeloma£ÛJ£Ý.Ann Hematol,2020,99(5):1049-1061.
£Û6£ÝH¦BJEK R,MINAR¦PK J,STRAUB J,et al.Ixazomib-lenalidomide-dexamethasone in routine clinical practice:effectiveness in relapsed/refractory multiple myeloma£ÛJ£Ý.Future Oncol,2021,17(19):2499-2512.
£Û7£ÝGHOSH N, TUCKER N, ZAHURAK M, et al.Clarithromycin overcomes resistance to lenalidomide and dexamethasone in multiple myeloma£ÛJ£Ý.Am J Hematol£¬2014,89(8):e116-e120.
£Û8£ÝRAJKUMARSV,DIMOPOULOSMA,PALUMBOA,et al.International myeloma working group updated criteria for the diagnosis of multiple myeloma£ÛJ£Ý.Lancet Oncol,2014,15(12):e538-e548.
£Û9£ÝRAJE NS,ANAISSIE E,KUMAR SK,et al.Consensus guidelines and recommendations for infection prevention in multiple myeloma:a report from the international myeloma working group£ÛJ£Ý.Lancet Haematol,2022,9(2):e143-e161.
£Û10£ÝRAJKUMAR SV.Multiple myeloma:2020 update on diagnosis, risk-stratification and management£ÛJ£Ý.Am J Hematol,2020,95(5):548-567.
£Û11£ÝFREITES-MARTINEZ A,SANTANA N,ARIAS-SANTIAGO S,et al.Using the common terminology criteria for adverse events(CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies£ÛJ£Ý.Actas Dermosifiliogr(Engl Ed),2021,112(1):90-92.
£Û12£ÝNI B,HOU J.Promising therapeutic approaches for relapsed/refractory multiple myeloma£ÛJ£Ý.Hematology,2022,27(1):343-352.
£Û13£ÝRICHARDSON PG,KUMAR SK,MASSZI T,et al.Final overall survival analysis of the TOURMALINE-MM1 phase III trial of ixazomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma£ÛJ£Ý.J Clin Oncol,2021,39(22):2430-2442.
£Û14£ÝIIDA S,IZUMI T,KOMENO T,et al.A phase 2,open-label,multicenter study of ixazomib plus lenalidomide and dexamethasone in adult Japanese patients with relapsed and/or refractory multiple myeloma£ÛJ£Ý.Int J Clin Oncol,2022,27(1):224-233.
£Û15£ÝTAKEMORI N,OOI HK,IMAI G,et al.Possible mechanisms of action of Clarithromycin and its clinical application as a repurposing drug for treating multiple myeloma£ÛJ£Ý.E Cancer Medical Science,2020,14:1088.
£Û16£ÝCOLEMAN M,LEONARD J,LYONS L,et al.BLT-D(Clarithromycin, low-dose thalidomide, and dexamethasone)for the treatment of myeloma and Waldenstr¢‰m's macro globulinemia£ÛJ£Ý.Leuk Lymphoma,2002,43(9):1777-1782.
£Û17£ÝGAY FRANCESCA,RAJKUMAR SV,COLEMAN M,et al.Clarithromycin(Biaxin)-lenalidomide-low-dose dexamethasone(BiRd) versus lenalidomide-low-dose dexamethasone(Rd) for newly diagnosed myeloma£ÛJ£Ý.Am J Hematol, 2010,85(9):664-669.
£Û18£ÝÁõÑ©Á«,Àîè´,Ê·ÇàÁÖ,µÈ.BiRd·½°¸ÖÎÁƸ´·¢ÄÑÖζ෢ÐÔ¹ÇËèÁöµÄ»Ø¹ËÐÔÑо¿£ÛJ£Ý.ÖлªÑªÒºÑ§ÔÓÖ¾,2017,38(10):837-841. LIU XL,LI L,SHI QL,et al.A retrospective study of BiRd regimen in the treatment of relapsed and refractory multiple myeloma£ÛJ£Ý.Chinese Journal of Hematology,2017,38(10):837-841.
£Û19£ÝKRISHNAN A,KAPOOR P,PALMERJ M,et al.Phase ¢ñ/¢ò trial of the oral regimen ixazomib,pomalidomide,and dexamethasone in relapsed/refractory multiple myeloma£ÛJ£Ý.Leukemia,2018,32(7):1567-1574.
£Û20£ÝATTAL M,RICHARDSON PG,RAJKUMAR SV,et al.Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma(ICARIA-MM):a randomised£¬multicentre£¬open-label,phase 3 study£ÛJ£Ý.Lancet,2019,394(10214):2096-2107.
£Û21£ÝRICHARDSON PG,SAN-MIGUEL J,BEKSAC M,et al.Updates from ICARIA-MM£¬a phase 3 study of isatuximab(Isa) plus pomalidomide and low-dose dexamethasone(Pd) versus Pd in relapsed and refractory multiple myeloma(RRMM)£ÛJ£Ý.J Clin Oncol,2021,39(15 Suppl)£º8017.

Memo

Memo:

ºÓÄÏʡҽѧ¿Æ¼¼¹¥¹Ø¼Æ»®ÁªºÏ¹²½¨ÏîÄ¿£¨±àºÅ£ºLHGJ20210533£©;ºÓÄÏÊ¡ÐÂÏçÊпƼ¼¹¥¹ØÏîÄ¿£¨±àºÅ£ºGG2020029£©

Common functions

Last Update: 2023-08-31